Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says
Bank of America raised its peak sales estimate for Johnson & Johnson's (JNJ) psoriasis drug Icotyde to $4.5B, up from $2.4B, and increased its price target to $278. The broker forecasts $70M in Q3 sales and $220M in 2026 sales, with limited changes to companywide 2026 sales forecasts. JNJ's earnings estimates were adjusted to reflect recent acquisitions and collaborations, with a Q3 EPS forecast of $2.53, below the consensus of $2.87.
How this was made
The 30-second read
Why it matters
The analyst upgrade provides a fresh catalyst that could drive short‑term buying pressure.
Market read
New analyst guidance on a high‑growth drug creates a short‑term trading opportunity for JNJ.
What to watch
Potential pricing pressure from competitors and reimbursement uncertainties could temper the rally.
Background
Bank of America updated its valuation multiples and sales forecasts for JNJ's new oral psoriasis drug, citing prescription data and sector rerating.
Ticker impact
Bank of America raised its price target for Johnson & Johnson to $278 and forecasted peak sales of $4.5B for the new psoriasis drug Icotyde, updating its 2027 earnings estimates.
potential modest upside as the market prices in the higher target and sales forecast
The new target and sales estimate represent fresh, material analyst guidance that can move the stock in the short term.
Market effects
Higher sales expectations for Icotyde may lift other dermatology and biotech peers.
U.S. pharma sector could see modest gains as defensive drug outlook improves.
Limited to investors tracking Johnson & Johnson and the broader healthcare sector.
Counterpoint
The forecast still falls short of consensus for 2030, suggesting upside may be limited.
Key entities
- companyJohnson & Johnson
U.S. healthcare conglomerate issuing the drug Icotyde.
- analystBank of America
Equity research firm raising price target and sales outlook.
